Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.

Solid Tumors Clinical Trial

Official title:

A Phase I Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02058901
• Other study ID #: 2013/75
• Secondary ID: 2012-005756-41
• Status: Completed
• Phase: Phase 1
• Start date: July 2013
• Est. completion date: June 2019

Study information

• Verified date: July 2019
• Source: VU University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is:

• To determine the maximum tolerated dose (MTD) of sunitinib when administered once weekly or once every two weeks.

• To assess the safety and tolerability of sunitinib in a once weekly or once every two weeks dose schedule.

Description:

Our hypothesis is that sunitinib, when given in a high-dose, intermittent schedule may exhibit improved efficacy with an acceptable toxicity profile. In the present phase I trial, we aim to determine the maximum tolerated dose of sunitinib when administered high-dose, once weekly or once every two weeks. Furthermore, by acquiring skin and tumor biopsies, we will assess intratumoral concentrations of sunitinib, correlate these to skin and plasma concentrations and gain more insight into the biological effects of the drug. Additionally, we aim to preliminary assess the efficacy of sunitinib administered at the MTD level in both schedules. Known serum angiogenesis markers will be correlated to efficacy endpoints.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: June 2019
• Est. primary completion date: June 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed (by the patient or legally acceptable representative) and dated Informed Consent Form

• Histological or cytological documentation of incurable locally advanced or metastatic solid malignancy for which no standard therapy exists.

• Primary tumor or metastatic site must be accessible for biopsy. Patients eligible for the expansion cohort must be willing to undergo tumor biopsies, while tumor biopsy remains optional for patients enrolled in the escalation cohort. Bone metastases are excluded as a biopsy site.

• Evaluable disease by RECIST version 1.1 criteria (see appendix III; at least 1 target or non-target lesion for dose escalation cohorts; at least 1 target lesion for dose expansion cohort).

• Patients must have documented radiographic or clinical progressive disease.

• Age = 18 years.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

• Normal 12-lead ECG (clinically insignificant abnormalities permitted), and Left Ventricular Ejection Fraction (LVEF) > 50% by multigated acquisition (MUGA) scan or echocardiogram.

• Normal regulated thyroid function- suppletion or blocking drugs permitted.

• Urinalysis: no clinically significant abnormalities.

• Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to screening:

1. Hemoglobin >= 5.6 mmol/l

2. Absolute neutrophil count (ANC) >=1,5 x 10*9/l

3. Platelet count >= 100 x 10*9/l

4. Total bilirubin <=1.5 times the upper limit of normal (ULN)

5. ALT and AST 2.5 x ULN (In case of liver metastases: < 5 x ULN)

6. Alkaline phosphatase < 4 x ULN

7. Serum creatinine <= 1.5 x ULN or Creatinine clearance >= 50 ml/min (based on MDRD)

8. PT-INR/PTT < 1.5 x ULN, unless coumarin derivatives are used

9. Activated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation therapy is allowed, if this treatment can be interrupted for a biopsy as judged by the treating physician)

• Patients with known Gilbert's disease who have serum bilirubin <= 3x ULN may be enrolled.

• Pregnant or breast-feeding subjects: Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. For fertile men or women of childbearing potential: documented willingness to use a highly effective means of contraception (e.g., hormonal methods [implants, injectables, or combined oral contraceptives], intrauterine devices, sexual abstinence, or vasectomized or surgically sterilized partner). Contraception is necessary for at least 6 months after receiving the study kinase inhibitor.

Exclusion Criteria:

• Evidence of a significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); nervous system, pulmonary (including obstructive pulmonary disease and history of symptomatic bronchospasm), renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture.

• Poorly controlled hypertension despite adequate blood pressure medication. Blood pressure must be =160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements.

• Seizure disorders requiring anticonvulsant therapy.

• jor surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery.

• Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds.)

• Known hypersensitivity to sunitinib or to its excipients.

• Presence of any significant central nervous system or psychiatric disorder(s) that would interfere with the patient's compliance.

• Drug or alcohol abuse.

• Females who are pregnant or breast-feeding.

• Any evidence of a disease or condition that might affect compliance with the protocol or interpretation of the study results or render the patient at high risk from treatment complications.

• Unwillingness or inability to comply with study and follow-up procedures.

• No chemotherapy, radiotherapy, or biologic therapy within the previous 4 weeks; no nitrosoureas or mitomycin C within the previous 6 weeks; no investigational agents within the previous 4 weeks.

• Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.

• Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control);

• Patients with a history of treated CNS metastases are eligible, provided that all of the following criteria are met:

1. Presence of evaluable or measurable disease outside the CNS

2. Radiographic demonstration of improvement upon completion of CNS-directed therapy and no evidence of interim progression between completion of CNS-directed therapy and the screening radiographic study

3. Completion of radiotherapy = 8 weeks prior to the screening radiographic study

4. Discontinuation of corticosteroids and anticonvulsants = 4 weeks prior to the screening radiographic study.

Note: Prior sunitinib therapy does not constitute an exclusion criterion.

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• Sunitinib

Locations

Country	Name	City	State
Netherlands	VU University Medical Center	Amsterdam

Sponsors (1)

Lead Sponsor	Collaborator
VU University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maximum tolerated dose (MTD) of sunitinib		6 weeks
Primary	Number of participants with serious and non-serious adverse events		6 weeks
Secondary	Calculation of maximum plasma drug concentration, sunitinib half life, Area Under the Concentration-Time Curve (AUC 0-48h), clearance and volume of distribution		Prior to the initial dose on day 1 and 2, 4, 6, 8, 10, 24, and 48 hours post-dose
Secondary	Time to Disease Progression		end of study
Secondary	Recommended phase II dose (RP2D) and the optimal dose schedule		End of study
Secondary	Measurement of intratumoral and skin concentration of sunitinib		2 weeks